|
1
|
Nattinger AB and Mitchell JL: Breast
cancer screening and prevention. Ann Intern Med. 164:ITC81–ITC96.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prat A, Cheang MC, Galván P, Nuciforo P,
Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, et al:
Prognostic value of intrinsic subtypes in hormone receptor-positive
metastatic breast cancer treated with letrozole with or without
lapatinib. JAMA Oncol. 2:1287–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maciejczyk A: New prognostic factors in
breast cancer. Adv Clin Exp Med. 22:5–15. 2013.PubMed/NCBI
|
|
6
|
Recondo G Jr, de la Vega M, Galanternik F,
Díaz-Cantón E, Leone BA and Leone JP: Novel approaches to target
HER2-positive breast cancer: Trastuzumab emtansine. Cancer Manag
Res. 8:57–65. 2016.PubMed/NCBI
|
|
7
|
Bianco S and Gévry N: Endocrine resistance
in breast cancer: From cellular signaling pathways to epigenetic
mechanisms. Transcription. 3:165–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giessrigl B, Schmidt WM, Kalipciyan M,
Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader RM and
Krupitza G: Fulvestrant induces resistance by modulating GPER and
CDK6 expression: Implication of methyltransferases, deacetylases
and the hSWI/SNF chromatin remodelling complex. Br J Cancer.
109:2751–2762. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marquette C and Nabell L:
Chemotherapy-resistant metastatic breast cancer. Curr Treat Options
Oncol. 13:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wallrapp C, Hähnel S, Müller-Pillasch F,
Burghardt B, Iwamura T, Ruthenbürger M, Lerch MM, Adler G and Gress
TM: A novel transmembrane serine protease (TMPRSS3) overexpressed
in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
|
|
11
|
Zhang D, Qiu S, Wang Q and Zheng J:
TMPRSS3 modulates ovarian cancer cell proliferation, invasion and
metastasis. Oncol Rep. 35:81–88. 2016.PubMed/NCBI
|
|
12
|
Rui X, Li Y, Jin F and Li F: TMPRSS3 is a
novel poor prognostic factor for breast cancer. Int J Clin Exp
Pathol. 8:5435–5442. 2015.PubMed/NCBI
|
|
13
|
Pelkonen M, Luostari K, Tengström M,
Ahonen H, Berdel B, Kataja V, Soini Y, Kosma VM and Mannermaa A:
Low expression levels of hepsin and TMPRSS3 are associated with
poor breast cancer survival. BMC Cancer. 15:4312015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dougall WC and Chaisson M: The
RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer
Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME and
Yu J: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nik-Zainal S, Davies H, Staaf J,
Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB,
Martin S, Wedge DC, et al: Landscape of somatic mutations in 560
breast cancer whole-genome sequences. Nature. 534:47–54. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu
W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park HR, Min SK, Cho HD, Kim DH, Shin HS
and Park YE: Expression of osteoprotegerin and RANK ligand in
breast cancer bone metastasis. J Korean Med Sci. 18:541–546. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suva LJ, Washam C, Nicholas RW and Griffin
RJ: Bone metastasis: Mechanisms and therapeutic opportunities. Nat
Rev Endocrinol. 7:208–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Lu J, Ji Y, Hong A and Xie Q:
Cytokines in osteoblast-conditioned medium promote the migration of
breast cancer cells. Tumour Biol. 35:791–798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hooper JD, Clements JA, Quigley JP and
Antalis TM: Type II transmembrane serine proteases. Insights into
an emerging class of cell surface proteolytic enzymes. J Biol Chem.
276:857–860. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luostari K, Hartikainen JM, Tengström M,
Palvimo JJ, Kataja V, Mannermaa A and Kosma VM: Type II
transmembrane serine protease gene variants associate with breast
cancer. PLoS One. 9:e1025192014. View Article : Google Scholar : PubMed/NCBI
|
